Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

Inclusion Criteria: * Males or non-pregnant females, ≥12 years of age, of any race or sex. Females of child-bearing potential must have a negative urine pregnancy test. * For minors (less than 18 years), the parent/legal guardian must complete the informed consent process AND the subject must complete the assent process and sign the appropriate form (if age appropriate). * Presence of interdigital only or both interdigital and moccasin types of tinea pedis on one or both feet characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling and mild pruritus) based on signs and symptoms in the affected area(s). Exclusion Criteria: * Subjects with life-threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable angina or myocardial infarction) within the last 6 months. * Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results. * Subjects with a known hypersensitivity to study drugs or their components. * Subjects who have a recent history or who are currently known to abuse alcohol or drugs. * Uncontrolled diabetes mellitus. * Hemodialysis or chronic ambulatory peritoneal dialysis therapy. * Current diagnosis of immunocompromising conditions. * Foot psoriasis, corns and/or callus involving any web spaces, atopic or contact dermatitis. * Severe dermatophytoses, onychomycosi…